On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff Dexcom ONE, a wearable sensor and transmitter, puts people firmly in control of their ...
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in ...
This year’s Diabetes Awareness Week (13-19 June) is celebrating the triumphs and challenges for all people with diabetes. To celebrate the week, as well as the updated NICE (National Institute of ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...
DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...
Barchart on MSN
DexCom Earnings Preview: What to Expect
Valued at a market cap of $25.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy growth stocks to buy now. On August 21, Argus initiated coverage of DexCom, Inc. (NASDAQ:DXCM) with a Buy rating and $100 price target. Why ...
Glucose monitor maker DexCom (DXCM 3.40%) has had a rough month. After a Wall Street analyst downgraded the stock Oct. 2 and sharply trimmed its price target, the price fell over the next 30 days, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback